Title:
EGFR SMALL MOLECULE INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/017258
Kind Code:
A1
Abstract:
Disclosed in the present invention are a multi-target small molecule inhibitor, a pharmaceutical composition containing same, and a use thereof. Specifically, the compound of the present invention has a structure as shown in formula (I). Further disclosed in the present invention are a preparation method for the compound and a use thereof as an EGFR inhibitor. The compound can be used for treating related diseases (such as cancer) mediated by EGFR, HER-2, c-MET and the like, and especially has a special effect on diseases (such as cancer) having resistance to early related drugs and caused by one or more gene mutations of EGFR dimutation and triple mutation, HER-2 amplification and exon20 mutation, c-MET amplification, and the like.
Inventors:
BAI HAIYUN (CN)
SU HAIYUN (CN)
LOU YANG (CN)
GAO ANHUI (CN)
ZHONG LI (CN)
SU HAIYUN (CN)
LOU YANG (CN)
GAO ANHUI (CN)
ZHONG LI (CN)
Application Number:
PCT/CN2023/107949
Publication Date:
January 25, 2024
Filing Date:
July 18, 2023
Export Citation:
Assignee:
BIOPOLAR HONGYE NANTONG PHARMACEUTICAL CO LT (CN)
International Classes:
C07D498/18; A61K31/529; A61P35/00; C07D239/88
Domestic Patent References:
| WO2021216440A1 | 2021-10-28 | |||
| WO2020009179A1 | 2020-01-09 | |||
| WO2021163627A1 | 2021-08-19 |
Foreign References:
| CN102143750A | 2011-08-03 | |||
| CN102718775A | 2012-10-10 | |||
| CN113956272A | 2022-01-21 |
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF: